8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Sep 29, 2025·SEC
Artivion, Inc.(AORT)Earnings, Financials & Key Ratios
AORT•NYSE
$34.70
$1.68B mkt cap·165.2× P/E·Price updated May 6, 2026
AboutArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.Show more
- Revenue$441M+13.6%
- EBITDA$49M-22.0%
- Net Income$10M+173.1%
- EPS (Diluted)0.21+165.6%
- Gross Margin61.28%-4.3%
- EBITDA Margin11.15%-31.3%
- Operating Margin6.06%-39.4%
- Net Margin2.21%+164.4%
- ROE2.7%+156.3%
- ROIC3.18%-36.3%
- Debt/Equity0.65-50.3%
- Interest Coverage1.01+28.9%
AORT Key Insights
Artivion, Inc. (AORT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 13.2% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AORT Price & Volume
Artivion, Inc. (AORT) stock price & volume — 10-year historical chart
Loading chart...
AORT Growth Metrics
Artivion, Inc. (AORT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.7%
5 Years11.75%
3 Years12.04%
TTM13.59%
Profit CAGR
10 Years9.33%
5 Years-
3 Years-
TTM173.12%
EPS CAGR
10 Years4.14%
5 Years-
3 Years-
TTM162.33%
Return on Capital
10 Years2.85%
5 Years2.33%
3 Years3.23%
Last Year3.55%
AORT Recent Earnings
Artivion, Inc. (AORT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 12, 2026EPS
$0.17
Est $0.14
+21.4%
Revenue
$116M
Est $116M
-0.4%
Q4 2025
Nov 6, 2025EPS
$0.16
Est $0.14
+14.3%
Revenue
$113M
Est $116M
-2.6%
Q3 2025
Aug 7, 2025EPS
$0.24
Est $0.11
+118.2%
Revenue
$113M
Est $107M
+5.1%
Q2 2025
May 5, 2025EPS
$0.06
Est $0.12
-50.0%
Revenue
$99M
Est $109M
-8.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $0.17vs $0.14+21.4% | $116Mvs $116M-0.4% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.14+14.3% | $113Mvs $116M-2.6% |
| Q3 2025 | Aug 7, 2025 | $0.24vs $0.11+118.2% | $113Mvs $107M+5.1% |
| Q2 2025 | May 5, 2025 | $0.06vs $0.12-50.0% | $99Mvs $109M-8.8% |
Based on last 12 quarters of dataView full earnings history →
AORT Peer Comparison
Artivion, Inc. (AORT) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NNOX | 117.04M | 1.79 | -1.97 | 13.91% | -452.82% | -35.55% | 0.04 | |
 TMDX | 2.52B | 72.92 | 14.97 | 37.13% | 27.04% | 41.92% | 0.99 | |
 MASI | 9.35B | 178.49 | -63.74 | -27.1% | 4.9% | 9.08% | 0.78 | |
 GMED | 12.07B | 89.22 | 22.76 | 16.65% | 18.3% | 12.4% | 0.03 | |
 LMAT | 2.51B | 110.22 | 43.74 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ANGO | 459.4M | 11.05 | -13.31 | -3.76% | -9.02% | -15.71% |
Compare AORT vs Peers
Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AORT Income Statement
Artivion, Inc. (AORT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 189.7M | 262.84M | 276.22M | 253.23M | 298.84M | 313.79M | 354M | 388.54M | 441.33M |
| Revenue Growth % | 5.17% | 38.55% | 5.09% | -8.32% | 18.01% | 5% | 12.82% | 9.75% | 13.59% |
| Cost of Goods Sold | 61.06M | 89.86M | 93.21M | 85.44M | 101.32M | 111.27M | 124.83M | 139.76M | 170.88M |
| COGS % of Revenue | 32.19% | 34.19% | 33.74% | 33.74% | 33.91% | 35.46% | 35.26% | 35.97% | 38.72% |
| Gross Profit | 128.64M▲ 0% | 172.98M▲ 34.5% | 183.01M▲ 5.8% | 167.78M▼ 8.3% | 197.51M▲ 17.7% | 202.52M▲ 2.5% | 229.18M▲ 13.2% | 248.78M▲ 8.6% | 270.45M▲ 8.7% |
| Gross Margin % | 67.81% | 65.81% | 66.26% | 66.26% | 66.09% | 64.54% | 64.74% | 64.03% | 61.28% |
| Gross Profit Growth % | 8.19% | 34.47% | 5.8% | -8.32% | 17.72% | 2.54% | 13.16% | 8.55% | 8.71% |
| Operating Expenses | 120.67M | 163.67M | 165.97M | 165.34M | 189.4M | 196.32M | 223.43M | 209.91M | 243.71M |
| OpEx % of Revenue | 63.61% | 62.27% | 60.09% | 65.29% | 63.38% | 62.57% | 63.12% | 54.02% | 55.22% |
| Selling, General & Admin | 101.21M | 140.57M | 143.01M | 141.14M | 169.77M | 157.44M | 208.98M | 192.38M | 212.72M |
| SG&A % of Revenue | 53.35% | 53.48% | 51.77% | 55.73% | 56.81% | 50.17% | 59.03% | 49.51% | 48.2% |
| Research & Development | 19.46M | 23.1M | 22.96M | 24.21M | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
| R&D % of Revenue | 10.26% | 8.79% | 8.31% | 9.56% | 11.89% | 12.39% | 8.11% | 7.32% | 7.02% |
| Other Operating Expenses | 260K | -141K | 0 | 0 | -15.92M | 0 | -14.25M | -10.92M | 0 |
| Operating Income | 7.97M▲ 0% | 9.31M▲ 16.8% | 17.04M▲ 83.0% | 2.44M▼ 85.7% | 8.12M▲ 232.5% | 6.2M▼ 23.6% | 5.74M▼ 7.4% | 38.87M▲ 577.0% | 26.75M▼ 31.2% |
| Operating Margin % | 4.2% | 3.54% | 6.17% | 0.96% | 2.72% | 1.98% | 1.62% | 10.01% | 6.06% |
| Operating Income Growth % | -63.47% | 16.84% | 83.01% | -85.68% | 232.53% | -23.6% | -7.4% | 577.01% | -31.2% |
| EBITDA | 17.7M | 27.41M | 35.36M | 23.15M | 32.09M | 28.64M | 28.82M | 63.08M | 49.2M |
| EBITDA Margin % | 9.33% | 10.43% | 12.8% | 9.14% | 10.74% | 9.13% | 8.14% | 16.23% | 11.15% |
| EBITDA Growth % | -41.39% | 54.82% | 29.01% | -34.52% | 38.62% | -10.75% | 0.61% | 118.89% | -22% |
| D&A (Non-Cash Add-back) | 9.73M | 18.09M | 18.32M | 20.71M | 23.98M | 22.44M | 23.08M | 24.2M | 22.46M |
| EBIT | 8.44M | 12.11M | 16.53M | -476K | 2.06M | 3.24M | 3.71M | 26.76M | 26.75M |
| Net Interest Income | -4.67M | -15.56M | -14.15M | -16.48M | -16.81M | -18.08M | -24.22M | -32.81M | -25.82M |
| Interest Income | 212K | 226K | 738K | 217K | 79K | 147K | 1.08M | 1.47M | 763K |
| Interest Expense | 4.88M | 15.79M | 14.89M | 16.7M | 16.89M | 18.22M | 25.3M | 34.28M | 26.58M |
| Other Income/Expense | -4.41M | -15.7M | -15.4M | -19.61M | -22.94M | -21.18M | -27.33M | -46.39M | -11.96M |
| Pretax Income | 3.56M▲ 0% | -6.39M▼ 279.5% | 1.64M▲ 125.7% | -17.17M▼ 1144.6% | -14.83M▲ 13.7% | -14.98M▼ 1.1% | -21.59M▼ 44.1% | -7.51M▲ 65.2% | 14.78M▲ 296.7% |
| Pretax Margin % | 1.88% | -2.43% | 0.6% | -6.78% | -4.96% | -4.78% | -6.1% | -1.93% | 3.35% |
| Income Tax | -143K | -2.59M | -76K | -492K | 7K | 4.21M | 9.1M | 5.84M | 5.01M |
| Effective Tax Rate % | -4.02% | 40.46% | -4.62% | 2.86% | -0.05% | -28.08% | -42.18% | -77.79% | 33.91% |
| Net Income | 3.7M▲ 0% | -3.81M▼ 202.7% | 1.72M▲ 145.2% | -16.68M▼ 1069.9% | -14.83M▲ 11.1% | -19.19M▼ 29.4% | -30.69M▼ 59.9% | -13.36M▲ 56.5% | 9.77M▲ 173.1% |
| Net Margin % | 1.95% | -1.45% | 0.62% | -6.59% | -4.96% | -6.12% | -8.67% | -3.44% | 2.21% |
| Net Income Growth % | -65.63% | -202.73% | 145.2% | -1069.88% | 11.08% | -29.38% | -59.91% | 56.47% | 173.12% |
| Net Income (Continuing) | 3.7M | -2.84M | 1.72M | -16.68M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.11▲ 0% | -0.10▼ 190.9% | 0.05▲ 145.1% | -0.44▼ 1075.6% | -0.38▲ 13.6% | -0.48▼ 26.3% | -0.75▼ 56.3% | -0.32▲ 57.3% | 0.21▲ 165.6% |
| EPS Growth % | -65.63% | -190.91% | 145.1% | -1075.61% | 13.64% | -26.32% | -56.25% | 57.33% | 165.63% |
| EPS (Basic) | 0.11 | -0.11 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.22 |
| Diluted Shares Outstanding | 34.16M | 36.41M | 37.86M | 37.86M | 38.98M | 40.03M | 40.74M | 41.68M | 47.16M |
| Basic Shares Outstanding | 33.01M | 35.16M | 37.12M | 37.86M | 38.98M | 40.03M | 40.74M | 41.68M | 45.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AORT Balance Sheet
Artivion, Inc. (AORT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 179.28M | 179.17M | 187.39M | 234.59M | 247.7M | 247.33M | 280.67M | 290.08M | 303.55M |
| Cash & Short-Term Investments | 40.75M | 41.49M | 33.77M | 61.41M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M |
| Cash Only | 40.75M | 41.49M | 33.77M | 61.41M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 51.44M | 51.43M | 55.86M | 48.75M | 58.1M | 69.58M | 74.14M | 85.89M | 103.68M |
| Days Sales Outstanding | 98.98 | 71.42 | 73.81 | 70.27 | 70.97 | 80.94 | 76.44 | 80.69 | 85.75 |
| Inventory | 46.68M | 45.48M | 53.07M | 73.04M | 76.97M | 74.48M | 81.98M | 79.77M | 92.43M |
| Days Inventory Outstanding | 279.06 | 184.73 | 207.82 | 312.01 | 277.28 | 244.32 | 239.7 | 208.32 | 197.43 |
| Other Current Assets | 36.45M | 33.92M | 33.08M | 37.09M | 42.86M | 46.37M | 49.8M | 70.96M | 42.54M |
| Total Non-Current Assets | 412.39M | 391.92M | 418.26M | 554.82M | 545.36M | 515.46M | 511.73M | 499.02M | 581.25M |
| Property, Plant & Equipment | 33.58M | 31.03M | 54.14M | 51.65M | 83.23M | 80.53M | 82.18M | 76.13M | 99.69M |
| Fixed Asset Turnover | 5.65x | 8.47x | 5.10x | 4.90x | 3.59x | 3.90x | 4.31x | 5.10x | 4.43x |
| Goodwill | 188.31M | 188.78M | 186.7M | 260.06M | 250M | 243.63M | 247.34M | 240.96M | 254.09M |
| Intangible Assets | 179.43M | 160.08M | 157.73M | 227.06M | 201.5M | 182.65M | 172.23M | 156.38M | 156.5M |
| Long-Term Investments | 1.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7.49M | 7.92M | 14.21M | 14.6M | 8.27M | 7.34M | 8.89M | 24.48M | 69.77M |
| Total Assets | 591.67M▲ 0% | 571.09M▼ 3.5% | 605.65M▲ 6.1% | 789.4M▲ 30.3% | 793.05M▲ 0.5% | 762.8M▼ 3.8% | 792.4M▲ 3.9% | 789.1M▼ 0.4% | 884.8M▲ 12.1% |
| Asset Turnover | 0.32x | 0.46x | 0.46x | 0.32x | 0.38x | 0.41x | 0.45x | 0.49x | 0.50x |
| Asset Growth % | 87.15% | -3.48% | 6.05% | 30.34% | 0.46% | -3.81% | 3.88% | -0.42% | 12.13% |
| Total Current Liabilities | 42.94M | 34.52M | 45.2M | 60.47M | 44.95M | 49.67M | 57.86M | 66.82M | 101.56M |
| Accounts Payable | 9.77M | 7.55M | 9.8M | 9.62M | 10.39M | 12M | 13.32M | 17.97M | 16.04M |
| Days Payables Outstanding | 58.38 | 30.66 | 38.36 | 41.11 | 37.45 | 39.38 | 38.94 | 46.93 | 34.27 |
| Short-Term Debt | 1.3M | 1.89M | 1.16M | 1.2M | 1.63M | 1.61M | 1.45M | 195K | 5.38M |
| Deferred Revenue (Current) | 29.45M | 2.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 12.06M | 13.86M | 14.07M | 29.37M | 700K | 1.31M | 21.11M | 583K | 50.17M |
| Current Ratio | 4.18x | 5.19x | 4.15x | 3.88x | 5.51x | 4.98x | 4.85x | 4.34x | 2.99x |
| Quick Ratio | 3.09x | 3.87x | 2.97x | 2.67x | 3.80x | 3.48x | 3.43x | 3.15x | 2.08x |
| Cash Conversion Cycle | 319.66 | 225.5 | 243.28 | 341.17 | 310.8 | 285.88 | 277.2 | 242.08 | 248.91 |
| Total Non-Current Liabilities | 269.69M | 261.5M | 274.76M | 400.22M | 447.37M | 428.79M | 452.75M | 446.08M | 335.01M |
| Long-Term Debt | 218.24M | 215.72M | 214.57M | 290.47M | 307.49M | 306.5M | 305.53M | 314.15M | 249.54M |
| Capital Lease Obligations | 6.86M | 5.94M | 23.33M | 19.33M | 49.24M | 44.9M | 47.38M | 42.82M | 37.13M |
| Deferred Tax Liabilities | 30.43M | 27.27M | 25.84M | 34.71M | 28.8M | 24.5M | 21.85M | 20.18M | 24.31M |
| Other Non-Current Liabilities | 14.17M | 12.58M | 11.02M | 55.71M | 61.84M | 52.9M | 77.99M | 68.92M | 24.03M |
| Total Liabilities | 312.63M | 296.02M | 319.96M | 460.69M | 492.32M | 478.47M | 510.62M | 512.9M | 436.56M |
| Total Debt | 226.39M | 223.55M | 245.15M | 317.37M | 362.04M | 356.83M | 358.34M | 362.26M | 292.04M |
| Net Debt | 185.63M | 182.06M | 211.39M | 255.96M | 307.03M | 317.48M | 299.4M | 308.8M | 227.13M |
| Debt / Equity | 0.81x | 0.81x | 0.86x | 0.97x | 1.20x | 1.25x | 1.27x | 1.31x | 0.65x |
| Debt / EBITDA | 12.79x | 8.16x | 6.93x | 13.71x | 11.28x | 12.46x | 12.43x | 5.74x | 5.94x |
| Net Debt / EBITDA | 10.49x | 6.64x | 5.98x | 11.06x | 9.57x | 11.08x | 10.39x | 4.90x | 4.62x |
| Interest Coverage | 1.73x | 0.77x | 1.11x | -0.03x | 0.12x | 0.18x | 0.15x | 0.78x | 1.01x |
| Total Equity | 279.04M▲ 0% | 275.07M▼ 1.4% | 285.7M▲ 3.9% | 328.71M▲ 15.1% | 300.73M▼ 8.5% | 284.33M▼ 5.5% | 281.78M▼ 0.9% | 276.2M▼ 2.0% | 448.23M▲ 62.3% |
| Equity Growth % | 33.52% | -1.42% | 3.86% | 15.06% | -8.51% | -5.45% | -0.9% | -1.98% | 62.29% |
| Book Value per Share | 8.17 | 7.55 | 7.55 | 8.68 | 7.71 | 7.10 | 6.92 | 6.63 | 9.50 |
| Total Shareholders' Equity | 279.04M | 275.07M | 285.7M | 328.71M | 300.73M | 284.33M | 281.78M | 276.2M | 448.23M |
| Common Stock | 376K | 385K | 390K | 404K | 414K | 418K | 426K | 434K | 493K |
| Retained Earnings | 37.61M | 34.98M | 36.7M | 20.02M | 1.98M | -17.22M | -47.91M | -61.27M | -51.5M |
| Treasury Stock | -12.72M | -14.59M | -14.59M | -14.65M | -14.65M | -14.65M | -14.65M | -14.65M | -14.65M |
| Accumulated OCI | 1.86M | -6.07M | -8.59M | 6.74M | -9.89M | -21.61M | -12.01M | -24.93M | -2.72M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AORT Cash Flow Statement
Artivion, Inc. (AORT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 10.8M | 9.88M | 15.83M | 12.37M | -2.58M | -5.15M | 18.82M | 22.24M | 38.13M |
| Operating CF Margin % | 5.69% | 3.76% | 5.73% | 4.88% | -0.86% | -1.64% | 5.32% | 5.72% | 8.64% |
| Operating CF Growth % | -45.22% | -8.53% | 60.18% | -21.85% | -120.9% | -99.34% | 465.32% | 18.12% | 71.48% |
| Net Income | 3.7M | -2.84M | 1.72M | -3.46M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M |
| Depreciation & Amortization | 9.74M | 18.09M | 18.32M | 27.86M | 23.98M | 22.44M | 23.08M | 24.2M | 22.46M |
| Stock-Based Compensation | 6.92M | 6.33M | 8.8M | 6.91M | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Deferred Taxes | -1.48M | -4.49M | -2.31M | 4.28M | -4.47M | -1.72M | -1.39M | -1.51M | 37K |
| Other Non-Cash Items | 2.79M | 2.8M | 8.68M | 3.47M | 15.26M | 6.91M | 29.59M | 15.9M | 3.64M |
| Working Capital Changes | -10.87M | -10.01M | -19.38M | -26.7M | -33.23M | -25.94M | -16.19M | -17.24M | -22.16M |
| Change in Receivables | -7.26M | -5.91M | -3.38M | 9.94M | -11.56M | -13.34M | -4.05M | -15.39M | -7.27M |
| Change in Inventory | -9.37M | 2.38M | -8.13M | -24.76M | -18.38M | -8.4M | -14.36M | -6.14M | -15.28M |
| Change in Payables | 8.73M | -8.87M | 251K | -9.16M | -1.89M | -1.96M | 1.68M | 9.5M | 2.18M |
| Cash from Investing | -170.99M | -6.71M | -23.94M | -73.13M | 5.66M | -10.71M | -502K | -28.19M | -42.04M |
| Capital Expenditures | -7.04M | -5.79M | -8.07M | -7.33M | -13.09M | -10.71M | -7.43M | -11.19M | -39.04M |
| CapEx % of Revenue | 3.71% | 2.2% | 2.92% | 2.89% | 4.38% | 3.41% | 2.1% | 2.88% | 8.85% |
| Acquisitions | -163.92M | 0 | 0 | -59.12M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -86K | -929K | -15.87M | -6.68M | -249K | 0 | 6.93M | -17M | -3M |
| Cash from Financing | 143.25M | -2.56M | -1.49M | 93.61M | -12.22M | -1.64M | 865K | 2.2M | 13.03M |
| Debt Issued (Net) | 152.79M | -2.79M | -2.78M | 94.65M | -3.08M | -2.75M | -2.77M | -358K | -2.46M |
| Equity Issued (Net) | -1.61M | -2.1M | -2.74M | -2M | -1.91M | -1.79M | -559K | 5.73M | 13.07M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.61M | -2.1M | -2.74M | -2M | -1.91M | -1.79M | -559K | 0 | 0 |
| Other Financing | -7.93M | 2.33M | 4.03M | 949K | -7.22M | 2.91M | 4.2M | -3.17M | 2.42M |
| Net Change in Cash | -16.66M▲ 0% | 1.48M▲ 108.9% | -7.94M▼ 635.5% | 27.66M▲ 448.3% | -6.95M▼ 125.1% | -15.66M▼ 125.4% | 19.59M▲ 225.1% | -5.48M▼ 128.0% | 11.45M▲ 309.0% |
| Free Cash Flow | 3.76M▲ 0% | 4.09M▲ 8.9% | 7.75M▲ 89.4% | 5.04M▼ 35.0% | -15.68M▼ 411.0% | -15.87M▼ 1.2% | 11.39M▲ 171.8% | 11.05M▼ 3.0% | -911K▼ 108.2% |
| FCF Margin % | 1.98% | 1.56% | 2.81% | 1.99% | -5.25% | -5.06% | 3.22% | 2.84% | -0.21% |
| FCF Growth % | -69.4% | 8.85% | 89.38% | -35% | -410.97% | -1.22% | 171.81% | -3.05% | -108.25% |
| FCF per Share | 0.11 | 0.11 | 0.20 | 0.13 | -0.40 | -0.40 | 0.28 | 0.27 | -0.02 |
| FCF Conversion (FCF/Net Income) | 2.92x | -2.60x | 9.20x | -0.74x | 0.17x | 0.27x | -0.61x | -1.66x | 3.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AORT Key Ratios
Artivion, Inc. (AORT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 5.92% | 1.52% | -1.37% | 0.61% | -5.43% | -4.71% | -6.56% | -10.84% | -4.79% | 2.7% |
| Return on Invested Capital (ROIC) | 9.77% | 1.74% | 1.52% | 2.68% | 0.34% | 1.02% | 0.77% | 0.73% | 5% | 3.18% |
| Gross Margin | 65.92% | 67.81% | 65.81% | 66.26% | 66.26% | 66.09% | 64.54% | 64.74% | 64.03% | 61.28% |
| Net Margin | 5.98% | 1.95% | -1.45% | 0.62% | -6.59% | -4.96% | -6.12% | -8.67% | -3.44% | 2.21% |
| Debt / Equity | 0.34x | 0.81x | 0.81x | 0.86x | 0.97x | 1.20x | 1.25x | 1.27x | 1.31x | 0.65x |
| Interest Coverage | 5.56x | 1.73x | 0.77x | 1.11x | -0.03x | 0.12x | 0.18x | 0.15x | 0.78x | 1.01x |
| FCF Conversion | 1.83x | 2.92x | -2.60x | 9.20x | -0.74x | 0.17x | 0.27x | -0.61x | -1.66x | 3.90x |
| Revenue Growth | 23.63% | 5.17% | 38.55% | 5.09% | -8.32% | 18.01% | 5% | 12.82% | 9.75% | 13.59% |
AORT SEC Filings & Documents
Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
AORT Frequently Asked Questions
Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Artivion, Inc. (AORT) reported $441.3M in revenue for fiscal year 2025. This represents a 1093% increase from $37.0M in 1996.
Artivion, Inc. (AORT) grew revenue by 13.6% over the past year. This is steady growth.
Yes, Artivion, Inc. (AORT) is profitable, generating $9.8M in net income for fiscal year 2025 (2.2% net margin).
Dividend & Returns
Artivion, Inc. (AORT) has a return on equity (ROE) of 2.7%. This is below average, suggesting room for improvement.
Artivion, Inc. (AORT) had negative free cash flow of $0.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More AORT
Artivion, Inc. (AORT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates